Opus Genetics announces upcoming presentations

Opus Genetics (IRD) announced presentations related to its IRD gene therapy programs at these upcoming scientific conferences in May: American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting, Title: Evaluation of MERTK gene therapy in RCS rats following a single bilateral subretinal injection, In this rat model of retinal degeneration, subretinal administration of OPGx-MERTK (1E10 vg/eye) demonstrated effective preservation of both photoreceptors and retinal function; American Ophthalmological Society (AOS) 2025 Annual Meeting, Title: Creation of Endpoints for the First Interventional Gene Therapy Clinical Study in BEST Disease using Animal Model and Natural History Data, Highlights: OPGx-BEST1 is being developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies, a form of macular degeneration found primarily in adults. Retinal Imaging Biomarkers and Endpoints Summit, Title: Utilizing VR Guided Multi Luminance Orientation and Mobility Testing for Assessment of Visual Function, Highlights: OPGx-BEST1 is being developed for bestrophin-1 (BEST1)-related inherited retinal diseases or bestrophinopathies, a form of macular degeneration found primarily in adults. Results from a preclinical study evaluating the safety and efficacy of OPGx-BEST1 in a canine model of BEST1 related IRD will be presented; Retinal Imaging Biomarkers and Endpoints Summit, Title: Utilizing VR Guided Multi Luminance Orientation and Mobility Testing for Assessment of Visual Function. The presentation will explore how virtual reality stimulators can help connect structural changes in the retina with functional outcomes.